![, ANZUP](https://anzup.org.au/wp-content/uploads/elementor/thumbs/Left-End-graphic-transparent-qqwmshz8l176rg0yx5m65bgxea55v39fx9qxkg0sg0.png)
Bladder, Urothelial and Penile Cancer (BUP) Subcommittee
ANNUAL
REPORT 2024
![, ANZUP](https://anzup.org.au/wp-content/uploads/elementor/thumbs/Right-End-graphic-transparent-qqwmshz8l176rg0yx5m65bgxea55v39fx9qxkg0sg0.png)
![, ANZUP](https://anzup.org.au/wp-content/uploads/elementor/thumbs/Right-End-graphic-transparent-qqwmshz8l176rg0yx5m65bgxea55v39fx9qxkg0sg0.png)
![, ANZUP](https://anzup.org.au/wp-content/uploads/elementor/thumbs/Right-End-graphic-transparent-qqwmshz8l176rg0yx5m65bgxea55v39fx9qxkg0sg0.png)
![, ANZUP](https://anzup.org.au/wp-content/uploads/elementor/thumbs/Left-End-graphic-transparent-qqwmshz8l176rg0yx5m65bgxea55v39fx9qxkg0sg0.png)
![, ANZUP](https://anzup.org.au/wp-content/uploads/elementor/thumbs/Left-End-graphic-transparent-qqwmshz8l176rg0yx5m65bgxea55v39fx9qxkg0sg0.png)
![, ANZUP](https://anzup.org.au/wp-content/uploads/elementor/thumbs/Left-End-graphic-transparent-qqwmshz8l176rg0yx5m65bgxea55v39fx9qxkg0sg0.png)
Bladder, Urothelial and Penile Cancer (BUP) Subcommittee
ANNUAL
REPORT 2024
![, ANZUP](https://anzup.org.au/wp-content/uploads/elementor/thumbs/Right-End-graphic-transparent-qqwmshz8l176rg0yx5m65bgxea55v39fx9qxkg0sg0.png)
![, ANZUP](https://anzup.org.au/wp-content/uploads/elementor/thumbs/Right-End-graphic-transparent-qqwmshz8l176rg0yx5m65bgxea55v39fx9qxkg0sg0.png)
![, ANZUP](https://anzup.org.au/wp-content/uploads/elementor/thumbs/Right-End-graphic-transparent-qqwmshz8l176rg0yx5m65bgxea55v39fx9qxkg0sg0.png)
ANNUAL REPORT 2024
Bladder, Urothelial and Penile Cancer (BUP) Subcommittee
Bladder, Urothelial and Penile Cancer (BUP) Subcommittee
![, ANZUP](https://anzup.org.au/wp-content/uploads/2023/07/Dickon-Hayne.jpg)
![, ANZUP](https://anzup.org.au/wp-content/uploads/2023/07/Dickon-Hayne.jpg)
Dickon Hayne
CHAIR
![, ANZUP](https://anzup.org.au/wp-content/uploads/2023/07/Andrew-Weickhardt.jpg)
![, ANZUP](https://anzup.org.au/wp-content/uploads/2023/07/Andrew-Weickhardt.jpg)
Andrew Weickhardt
DEPUTY CHAIR
We’re excited to share an update on the progress and achievements over the past year. We extend our sincere gratitude to Shomik Sengupta for his invaluable contributions as the Deputy Chair. As we look ahead, we warmly welcome Andrew Weickhardt as he steps into this pivotal role.
Trial Updates
BCGMM and beyond
The study has successfully completed recruitment with 501 patients. We anticipate the study to ready out in Q1/Q2 2025.
Further early translational work examining prognostic and predictive immune based biomarkers is ongoing with early data to be presented at #ANZUP24 ASM. Further studies are planned, aiming to utilise artificial intelligence to predict which patients will respond to BCGMM.
![, ANZUP](https://anzup.org.au/wp-content/uploads/2024/05/BCGMM_full-recruitment.png)
![, ANZUP](https://anzup.org.au/wp-content/uploads/2024/05/BCGMM_full-recruitment.png)
PCR-MIB (Addition of the PD1 inhibitor pembrolizumab to chemo-radiation for muscle invasive bladder cancer)
The manuscript has been published in European Urology Oncology. Longer-term follow up data for survival and relapse outcomes will be collected from sites later in 2024. In addition, the translational sub-study in collaboration with MSD is progressing well.
![, ANZUP](https://anzup.org.au/wp-content/uploads/2024/05/PCR-MIB-published-in-EUO.png)
![, ANZUP](https://anzup.org.au/wp-content/uploads/2024/05/PCR-MIB-published-in-EUO.png)
Below the Belt Funded Projects
ANZUP Co-operative multi-centre cystectomy database & ACCEPT-U
The Urological Society of Australia and New Zealand (USANZ) has expressed interest in seeking funding for national cystectomy database and are seeking collaboration from other groups already involved in this data collection.
The ACCEPT database has 548 cystectomy cases currently. ANZUP will continue with the project and encourage more sites to join while the USANZ project is in development.
Exciting progress has been made with HREC approval for the ACCEPT-U database. A guideline for sites to join ACCEPT/ACCEPT-U has been developed.
Furthermore, a combined retrospective analysis of nephroureterectomies from the ACCEPT-U database is being written up for publication. Some of these data were presented at the USANZ meeting.
Utilising a pro‐inflammatory gene signature and immune cell markers to identify non‐muscle invasive bladder cancer patients at high risk of intravesical BCG failure
As of February 29, 2024, Monash Pathology has prepared 16 out of 50 samples (from 25 patients pre- and post-treatment) for staining and sequencing. Our goal is to compile this data for presentation at the ANZUP Annual Scientific Meeting (ASM) in July 2024 and a European meeting later this year.
The MBC Trial ‐ Assessment of the diagnostic utility of multi‐parametric MRI Before cystoscopy in patients presenting with a bladder mass: a multicentre prospective study
As of 31 March, we’ve successfully recruited 61 out of 100 patients for the study. VIRADS 4/5 is strongly predictive as a cut-off for T2 disease. Additionally, the kurtosis value shows a correlation with tumour grade and serves as a predictive marker for muscle invasive disease. To extend the study to other sites, we’ll need both funding and buy-in from site radiologists.
Concepts
WAter or Chemotherapy to prevent Urothelial carcinoma a pre-imPlantation (WACUP) and Feasibility of Water Irrigation post TURBT for NMIBC
The pilot study manuscript has been accepted for publication. Furthermore, a systematic review conducted as part of the pilot study has been cited in the new European guidelines. The reference states that when intravesical chemotherapy is not possible, consider intravesical irrigation (saline or water). Grant applications have been submitted for support of a larger planned trial.
![, ANZUP](https://anzup.org.au/wp-content/uploads/2024/05/Water-irrigation-during-after-TURBT-to-reduce-recurrences.png)
![, ANZUP](https://anzup.org.au/wp-content/uploads/2024/05/Water-irrigation-during-after-TURBT-to-reduce-recurrences.png)
Genomic & immunological predictors of response to intravesical therapy
PD-L1 expression is being analysed in samples from 20 patients who received BCG.
SUBDUE-1: SUB-urothelial Durvalumab InjEction-1
The manuscript has been published in the British Journal of Urology International in March 2024.
![, ANZUP](https://anzup.org.au/wp-content/uploads/2024/05/SUBDUE-1-in-BJUI.png)
![, ANZUP](https://anzup.org.au/wp-content/uploads/2024/05/SUBDUE-1-in-BJUI.png)
ZIPUP – Zirconium-89-Girentuximab PET in Urothelial Cancer Patients
13/20 patients have been recruited for this study, as of 31 March 2024.
SUBDUE-3: Phase 0 study of SUB-urothelial DUrvalumab-Zirconium to investigate local and systemic distribution of Durvalumab when injected in the sub-urothelium
SUBDUE-3 has secured some limited funding and drug supply for proof of principle study (1-3 patients). The protocol is currently under development.